Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Yong, K;
Rabin, N;
... Wechalekar, AD; + view all
(2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
British Journal of Haematology
, 187
(5)
pp. 638-641.
10.1111/bjh.16122.
Preview |
Text
Manwani et al_AAM_Carfilzomib paper BJH 2.pdf - Accepted Version Download (535kB) | Preview |
Abstract
Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy. Carfilzomib, a second‐generation proteosomal inhibitor, results in a lower incidence of neuropathy than bortezomib, but data in AL is scant. We report a cohort of five AL patients treated with upfront carfilzomib. All had cardiac, peripheral and autonomic neuropathy at presentation. All achieved at least a very good partial haematological response. There was no worsening in cardiac function, peripheral or autonomic neuropathy. Carfilzomib is an effective upfront treatment option in AL patients with peripheral and/or autonomic neuropathy (without severe cardiac or renal involvement).
Archive Staff Only
 |
View Item |
